TAROのチャート
TAROの企業情報
| symbol | TARO |
|---|---|
| 会社名 | Taro Pharmaceutical Industries Ltd. （TARO PHARM INDUS） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | タロ・ファーマスーティカル・インダストリーズ(Taro Pharmaceutical Industries Ltd.)は科学ベースの製薬会社である。同社は、Taro Pharmaceutical Industries Ltd. (Taro Israel)及びTaro Pharmaceuticals Inc.(Taro Canada)とTaro U.S.A.という2つの子会社により構成される。同社は25以上の国において医薬品を販売する。同社所有の製品ブランドには、アセトアミノフェン、コデイン、カフェイン等の一般名を持つ「Rokacet」、デスオキシメタゾンという一般名を持つ「Topicort」、エトドラクという一般名を持つ「Etopan」、マラチオンという一般名の「Ovide」等を含む。同社の他のジェネリック医薬品には、アセトアゾラミド、アダパレン、ジプロピオネート、塩酸アミオダロン、乳酸アンモニウム、ジプロピオン酸ベタメタゾン、塩酸セチリジン、プロピオン酸クロベタゾール、塩酸クロミプラミン、ジクロロカリウム塩、フルオロウラシル、ケトコナゾール、メトロニダゾール、ムピロシン及びワルファリンナトリウム等を含む。 タロ・ファ―マシュ―ティカル・インダストリ―ズは、多国籍、科学に基づいたイスラエルの製薬会社。主に米国、カナダ、イスラエルで処方箋薬と薬局で自由に買える医薬品を開発、製造、販売する。主な分野は、皮膚科、心臓血管、神経精神及び抗炎症治療分野などへ向けクリ―ム、軟膏、液体、カプセル剤および錠剤を提供する。 Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. |
| 本社所在地 | 14 Hakitor Street Haifa Bay 26110 ISR |
| 代表者氏名 | Dilip Shantilal Shanghvi |
| 代表者役職名 | Chairman of the Board |
| 電話番号 | +972 4-847-5700 |
| 設立年月日 | 1959年 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 1490人 |
| url | www.taro.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） 309.86900 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 4129.03000 |
| 売上高 | （百万ドル） 665.18800 |
| 企業価値(EV) | （百万ドル） 3073.97900 |
| 当期純利益 | （百万ドル） 309.76400 |
| 決算概要 | BRIEF: For the nine months ended 31 December 2018 Taro Pharmaceutical Industries Ltd. revenues increased 1% to $490M. Net income before extraordinary items increased 79% to $223.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Foreign exchange (income) expense increase from $48.5M (expense) to $34.7M (income). |
TAROのテクニカル分析
TAROのニュース
Taro Pharmaceutical Industries (NYSE:TARO) Upgraded to “Buy” by StockNews.com 2023/04/26 07:26:41 The AM Reporter
StockNews.com upgraded shares of Taro Pharmaceutical Industries (NYSE:TARO – Get Rating) from a hold rating to a buy rating in a research note published on Tuesday. Separately, HC Wainwright cut their target price on Taro Pharmaceutical Industries from $54.00 to $35.00 and set a buy rating for the company in a research note on Wednesday, […]
Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield 2023/02/24 05:18:57 Seeking Alpha
Taro Pharmaceutical''s quarterly numbers came in with very thin growth at the operating and bottom-lines. Read more to learn why TARO stock is currently a Hold.
Taro Pharma Misses Q4 EPS by 68c By Investing.com 2023/01/24 23:28:01 Investing.com
Taro Pharma Misses Q4 EPS by 68c
Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M 2023/01/24 23:03:24 Seeking Alpha
Taro Pharmaceutical press release (NYSE:TARO): Q3 GAAP EPS of $0.19 misses by $0.68.Revenue of $139.2M misses by $23.92M.
Taro Pharmaceutical Indus''s Earnings Outlook 2023/01/23 16:01:49 Benzinga
Taro Pharmaceutical Indus (NYSE: TARO ) is set to give its latest quarterly earnings report on Tuesday, 2023-01-24. Here''s what investors need to know before the announcement. Analysts estimate that Taro Pharmaceutical Indus will report an earnings per share (EPS) of $0.87. Taro Pharmaceutical Indus bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com
Taro Pharma Misses Q4 EPS by 68c By Investing.com 2023/01/24 23:28:01 Investing.com
Taro Pharma Misses Q4 EPS by 68c
Taro Pharmaceutical GAAP EPS of $0.19 misses by $0.68, revenue of $139.2M misses by $23.92M 2023/01/24 23:03:24 Seeking Alpha
Taro Pharmaceutical press release (NYSE:TARO): Q3 GAAP EPS of $0.19 misses by $0.68.Revenue of $139.2M misses by $23.92M.
Taro Pharmaceutical Indus''s Earnings Outlook 2023/01/23 16:01:49 Benzinga
Taro Pharmaceutical Indus (NYSE: TARO ) is set to give its latest quarterly earnings report on Tuesday, 2023-01-24. Here''s what investors need to know before the announcement. Analysts estimate that Taro Pharmaceutical Indus will report an earnings per share (EPS) of $0.87. Taro Pharmaceutical Indus bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for … Full story available on Benzinga.com
Sun Pharma Q2 Preview: Higher costs, price erosion to mar profitability 2022/10/31 15:09:46 Economic Times India
The operational performance, however, will be hit by higher research and development costs, input prices, and continued erosion in prices in the US generics market. Sun Pharma’s US-based subsidiary Taro Pharmaceutical Industries, which released Q2 earnings last week, reported an operating loss of $6.8 million against a profit of $24.4 million a year ago, primarily due to pricing pressure in the generics drug market.
Taro Pharmaceutical Non-GAAP EPS of $0.66 misses by $0.18, revenue of $130.5M misses by $ 2022/10/28 06:07:47 Seeking Alpha
Taro Pharmaceutical press release (TARO): FQ2 Non-GAAP EPS of $0.66 misses by $0.18.Revenue of $130.5M (-11.3% Y/Y) misses by $30.52M.Gross profit of $47.0M (36.0% of net…
Taro Pharmaceutical GAAP EPS of $0.73, revenue of $143.26M 2022/05/27 06:10:18 Seeking Alpha
Taro Pharmaceutical press release (TARO): Q4 GAAP EPS of $0.73.Revenue of $143.26M (-3.4% Y/Y).
Taro Provides Results for the Year Ended March 31, 2022 2022/05/26 23:00:00 Wallstreet:Online
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2022. Quarter ended March 31, 2022 Highlights ─ compared to March 31, 2021 The quarter ended March 31, 2022, includes one month’s results from the February 28th acquisition of Alchemee. Net sales of $143.3 million
Taro Pharmaceutical Industries Shares Fall 0.5% Below Previous 52-Week Low - Market Mover 2022/05/26 00:00:00 Kwhen Finance
Taro Pharmaceutical Industries (TARO) shares closed 0.5% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 26.9% year-to-date, down 47.9% over the past 12 months, and down 60.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.8%, and the S&P 500 rose 1.4%. Trading Activity Trading volume this week was 105.3% higher than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold.
Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -445.6% The company's stock price performance over the past 12 months lags the peer average by -421.7%
This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
Taro Pharmaceutical Q1 2022 Earnings Preview 2022/05/25 21:35:56 Seeking Alpha
Taro Pharmaceutical (TARO) is scheduled to announce Q1 earnings results on Thursday, May 26th, after market close.The consensus EPS Estimate is $0.88 (+8.6% Y/Y) and the consensus…
Sensex Zooms 1,223 Points, Nifty Settles Above 16,300; Asian Paints, M&M and Bajaj Finance Surge 5% 2022/03/09 10:30:00 EquityMaster
Posted by Equitymaster Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note. Benchmark indices added to yesterday''s gains following a clawback in European markets and US futures as smart investors saw value in the current market valuations. The Sensex reclaimed 54,600 levels while the Nifty clawed back to 16,300 levels led by media, realty, and auto stocks. The sharp rally comes on hopes of de-escalation of the Russia-Ukraine conflict after the Ukrainian President Zelenskyy indicated that the country was no longer interest in NATO membership, the main reason behind the war. At the closing bell, the BSE Sensex stood higher by 1,223 points (up 2.3%). Meanwhile, the NSE Nifty closed higher by 332 points (up 2.1%). Asian Paints and Reliance Industries were among the top gainers today . Shree Cement and ONGC, on the other hand, were among the top losers today . The SGX Nifty was trading at 16,350, up by 408 points, at the time of writing.